

Lucemyra (lofexidine)
Effective 08/01/2019

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Lucemyra (lofexidine) is a central alpha-2 adrenergic agonist used to mitigate opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

Coverage Guidelines

Must meet all the following and documentation is submitted

1. Medication is being used to facilitate abrupt opioid discontinuation
2. Member is at least 18 years of age
3. Member has had an adverse reaction or inadequate response or a contraindication to oral clonidine
4. Opioid medications have been discontinued
5. Requested duration of therapy is 14 days or less

Continuation of Therapy

Reauthorization may be granted intervals when all the following criteria have been met:

1. Physician assessment is provided documenting member's clinical response
2. Member has not filled opioid medications
3. Physician is titrating dose down based on member's response.

Limitations

1. Approvals will be granted for 14 days
2. The following quantity limits apply:

Lucemyra	0.72mg (4x0.18mg tablets) four times a day
----------	--

	If Lucemyra was initiated in an inpatient setting, the total course of therapy should not exceed 14 days.
--	---

References

1. Lucemyra (lofexidine) [prescribing information]. Louisville, KY: US WorldMeds, LLC; September 2020
2. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. *J Addict Med.* 2015;9(5):358-367. doi: 10.1097/ADM.000000000000166
3. Akhurst JS. Lofexidine in opiate withdrawal: a safety and usage survey. *Pharmacoepidemiol Drug Saf.* 2000;9(1):43-47
4. Catapres (clonidine hydrochloride) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; August 2016
5. Sevarino K. Medically supervised opioid withdrawal during treatment for addiction. Post TW, ed. *UpToDate.* Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed December 21, 2017
6. Gowing L, Farrell M, Ali R, White JM. Alpha₂-adrenergic agonists for the management of opioid withdrawal. *Cochrane Database Syst Rev.* 2016;3(5):CD002024. doi: 10.1002/14651858

Review History

04/17/18 – Reviewed

08/01/19 – Implemented

09/22/2021- Reviewed Sept P&T; references updated no clinical changes.

